- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction to: AVT04: An Ustekinumab Biosimilar ; volume:44 ; number:10 ; day:28 ; month:9 ; year:2024 ; pages:799 ; date:10.2024
Clinical drug investigation ; 44, Heft 10 (28.9.2024), 799, 10.2024
- Urheber
-
Blair, Hannah A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-024-01393-9
- URN
-
urn:nbn:de:101:1-2501122118092.034885938120
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Blair, Hannah A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab